182 related articles for article (PubMed ID: 25187457)
1. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
Wang QF; Ding H; Liu BR; Zhang K
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
[TBL] [Abstract][Full Text] [Related]
2. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
3. Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors.
Wang Q; Ding H; Wang H; Li P; Liu B; Zhang K
Oncol Rep; 2015 Jan; 33(1):179-84. PubMed ID: 25354531
[TBL] [Abstract][Full Text] [Related]
4. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ
J Biol Chem; 2009 Jul; 284(28):19018-26. PubMed ID: 19435886
[TBL] [Abstract][Full Text] [Related]
5. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
[TBL] [Abstract][Full Text] [Related]
6. Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors.
Wang Q; Ding H; Liu B; Li SH; Li P; Ge H; Zhang K
Int J Oncol; 2014 Apr; 44(4):1277-83. PubMed ID: 24452693
[TBL] [Abstract][Full Text] [Related]
7. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
Simond AM; Rao T; Zuo D; Zhao JJ; Muller WJ
Oncogene; 2017 Oct; 36(43):6059-6066. PubMed ID: 28783168
[TBL] [Abstract][Full Text] [Related]
8. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis.
Dourdin N; Schade B; Lesurf R; Hallett M; Munn RJ; Cardiff RD; Muller WJ
Cancer Res; 2008 Apr; 68(7):2122-31. PubMed ID: 18381417
[TBL] [Abstract][Full Text] [Related]
9. In MMTV-Her-2/neu transgenic mammary tumors the absence of caveolin-1-/- alters PTEN and NHERF1 but not β-catenin expression.
Cuello-Carrión FD; Cayado-Gutiérrez N; Natoli AL; Restall C; Anderson RL; Nadin S; Alvarez-Olmedo D; Castro GN; Gago FE; Fanelli MA; Ciocca DR
Cell Stress Chaperones; 2013 Sep; 18(5):559-67. PubMed ID: 23397229
[TBL] [Abstract][Full Text] [Related]
10. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
[TBL] [Abstract][Full Text] [Related]
11. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
12. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
13. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
So JY; Wahler JE; Yoon T; Smolarek AK; Lin Y; Shih WJ; Maehr H; Uskokovic M; Liby KT; Sporn MB; Suh N
Cancer Prev Res (Phila); 2013 Sep; 6(9):959-70. PubMed ID: 23856074
[TBL] [Abstract][Full Text] [Related]
14. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
15. MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer.
Menezes ME; Shen XN; Das SK; Emdad L; Guo C; Yuan F; Li YJ; Archer MC; Zacksenhaus E; Windle JJ; Subler MA; Ben-David Y; Sarkar D; Wang XY; Fisher PB
Oncotarget; 2015 Nov; 6(35):36928-42. PubMed ID: 26474456
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
Fry EA; Taneja P; Inoue K
Int J Cancer; 2017 Feb; 140(3):495-503. PubMed ID: 27553713
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.
Raghuram N; Temel EI; Kawamata T; Kozma KJ; Loch AJ; Wang W; Adams JR; Muller WJ; Egan SE
Breast Cancer Res; 2024 May; 26(1):86. PubMed ID: 38807216
[TBL] [Abstract][Full Text] [Related]
18. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
19. Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways.
Andrade-Vieira R; Xu Z; Colp P; Marignani PA
PLoS One; 2013; 8(2):e56567. PubMed ID: 23451056
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
